

Tel: 400-999-8863 
■ Email:Upingbio.163.com





# PPAR-γ Polyclonal Antibody

| Catalog No         | YP-Ab-03325   |
|--------------------|---|
| Isotype            | IgG   |
| Reactivity         | Human;Mouse;Rat   |
| Applications       | IF;WB;IHC;ELISA   |
| Gene Name          | PPARG   |
| Protein Name       | Peroxisome proliferator-activated receptor gamma  |
| Immunogen          | The antiserum was produced against synthesized peptide derived from human PPAR-gamma. AA range:78-127   |
| Specificity        | PPAR-γ Polyclonal Antibody detects endogenous levels of PPAR-γ protein.   |
| Formulation        | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.   |
| Source             | Polyclonal, Rabbit,IgG  |
| Purification       | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.   |
| Dilution           | IF: 1:50-200 Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications.   |
| Concentration      | 1 mg/ml   |
| Purity             | ≥90%  |
| Storage Stability  | -20°C/1 year  |
| Synonyms           | PPARG; NR1C3; Peroxisome proliferator-activated receptor gamma; PPAR-gamma; Nuclear receptor subfamily 1 group C member 3   |
| Observed Band      | 57kD  |
| Cell Pathway       | Nucleus. Cytoplasm. Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner. NOCT enhances its nuclear translocation.  |
| Tissue Specificity | Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.   |
| Function           | alternative products:Additional isoforms seem to exist, disease:Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia., disease:Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension., disease:Defects in PPARG may be associated with colon cancer., disease:Defects in PPARG may be associated with susceptibility to obesity [MIM:601665]., disease:Variation in PPARG is associated with carotid intimal medial thickness 1 (CIMT1) [MIM:609338]. CIMT is a measure of atherosclerosis that is independently associated with traditional atherosclerotic cardiovascular disease |



### UpingBio technology Co.,Ltd

📞 Tel: 400-999-8863 🗷 Emall:Upingbio.163.com



#### **Background**

peroxisome proliferator activated receptor gamma(PPARG) Homo sapiens This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008],


## matters needing attention

Avoid repeated freezing and thawing!


### **Usage suggestions**

This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.


### **Products Images**




Immunofluorescence analysis of rat-lung tissue. 1,PPAR-γ Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-lung tissue. 1,PPAR-y Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B



Immunofluorescence analysis of rat-kidney tissue. 1,PPAR-γ Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B



Immunofluorescence analysis of rat-kidney tissue. 1,PPAR-y Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B



Immunofluorescence analysis of mouse-kidney tissue. 1,PPAR-y Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B